1,094 Shares in Cencora, Inc. $COR Acquired by Purkiss Capital Advisors LLC

Purkiss Capital Advisors LLC purchased a new position in shares of Cencora, Inc. (NYSE:COR) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,094 shares of the company’s stock, valued at approximately $328,000.

A number of other institutional investors and hedge funds have also made changes to their positions in COR. Golden State Wealth Management LLC increased its stake in Cencora by 157.6% during the first quarter. Golden State Wealth Management LLC now owns 170 shares of the company’s stock worth $47,000 after acquiring an additional 104 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Cencora by 30.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 41,927 shares of the company’s stock worth $11,539,000 after acquiring an additional 9,890 shares during the last quarter. Convergence Financial LLC acquired a new stake in Cencora during the 1st quarter worth approximately $228,000. Essex Financial Services Inc. acquired a new stake in Cencora during the 1st quarter worth approximately $210,000. Finally, Amalgamated Bank increased its position in Cencora by 2.8% during the 1st quarter. Amalgamated Bank now owns 38,869 shares of the company’s stock worth $10,809,000 after purchasing an additional 1,072 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on COR shares. Weiss Ratings reissued a “buy (b)” rating on shares of Cencora in a research report on Wednesday, October 8th. UBS Group increased their price target on Cencora from $350.00 to $380.00 and gave the company a “buy” rating in a report on Monday. Mizuho increased their price target on Cencora from $316.00 to $334.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Jefferies Financial Group increased their price target on Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a report on Monday, June 30th. Finally, Evercore ISI set a $340.00 target price on Cencora in a research note on Wednesday, October 8th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus target price of $329.00.

Cencora Price Performance

Shares of NYSE COR opened at $336.00 on Tuesday. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $336.07. The business has a 50 day moving average price of $305.00 and a two-hundred day moving average price of $295.60. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The firm has a market cap of $65.14 billion, a PE ratio of 34.57, a price-to-earnings-growth ratio of 1.55 and a beta of 0.63.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. During the same quarter last year, the company earned $3.34 earnings per share. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. Sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 15th. Cencora’s dividend payout ratio (DPR) is currently 22.63%.

Insider Buying and Selling at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,544 shares of company stock valued at $12,230,941. 10.80% of the stock is owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.